Like Bio-Hermes-001, the Bio-Hermes-002 study is paving the way for improving participation by trial participants who are traditionally underrepresented in Alzheimer’s clinical research, with an ...

Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema treatment, Dupixent, and announced a dividend and stock buyback program ...

Backed by Goldman Sachs, Novo Nordisk’s parent company and others, Newleos Therapeutics debuted Thursday with $94 million and ...

Art Basel returns for a 55th edition with 291 exhibitors and a new section dedicated to work made in the last five years.

UBS upgraded Roche (RHHBY) to Buy from Neutral with a price target of CHF 338, up from CHF 300. The company offers sustainable growth with ...

Evrysdi is the only non-invasive disease-modifying SMA treatment and is approved in over 100 countries Evrysdi tablet can be ...

Thomas Schinecker, CEO of Swiss pharma firm Roche, has dismissed fears that the company's sales targets would be threatened ...

We recently published a list of 10 Best Annual Dividend Stocks To Buy Now. In this article, we are going to take a look at ...

Fresh off the heels of winning the bid to host the Eurovision Song Contest in 2025, after Swiss contestant and first openly nonbinary performer Nemo won the contest last year, Basel is ready for its ...

It is strongly recommended that you apply for a Zoning Applicable Law Certificate Program (ZAP) to confirm that your property is subject to Site Plan Control approval. The ZAP review will also ...